Cancer Gene Therapy Market– By Type Of Therapy, Application, End User & Region - Forecast to 2023-2033
Category: Life Sciences Published Date : Jun-23 ID: CVC-48708 Format: PDF Pages: 300
Report Highlights According to a research survey conducted by ChemView Consulting, the Cancer Gene Therapy Market was worth US$ 2.4 Bn. The market is expected to grow at a CAGR of 19.99% between the 2023 to 2033 to reach US$ 15.0 Bn.
“Research Scope/Taxonomy:
“
Key Companies Profiled:
1.1. Global Market Snapshot
1.2. Key Success Factors
1.3. Strategic Analysis and Recommendations
2.1. Market Taxonomy
2.2. Market Definitions
3.1. Preliminary Investigation & Research Design
3.2. Secondary Research & Primary Research
3.3. Data Analysis & Econometric Modelling
3.4. Expert Data Validation
4.1. Supply-Side Trends
4.2. Demand-Side Trends
5.1. Global Market Value (US$ Mn) Analysis, 2018 – 2033
5.2. Incremental $ Opportunity Index, 2023-2033
5.3. Global Market Volume Analysis, 2018 – 2033
6.1. Regional Level Pricing Analysis and Forecast
6.1.1. Manufacturers Level Pricing
6.1.2. Distributor Level Pricing
6.2. Global Pricing Analysis Benchmark
6.3. Cost Breakdown Analysis
7.1. Cross Analysis of Application W.R.T. Product Type
8.1. Regional Supply Vs. Demand Gap Assessment
8.2. Top Producing Countries Analysis
9.1. Macroeconomic Factors
9.2. Forecast Factors
9.3. Market Dynamics
9.3.1. Driver
9.3.2. Restraint
9.3.3. Opportunity
9.4. Supply Chain Analysis
9.4.1. List Raw Material Suppliers
9.4.2. List of Manufacturers
9.4.3. List of Distributors
9.4.4. List of End-Users
9.4.5. End-Users Consumption Analysis
9.4.6. Average Profitability Margin Analysis
9.5. Covid-19 Impact Assessment
9.5.1. Economy/Cluster Projections
9.5.2. Covid-19 Economic Assessment
9.5.3. Impact on Target Market
9.5.4. Recovery Scenario
9.6. Regulatory Framework
9.6.1. Regulations of Key Countries
9.6.2. Potential Impact of Regulations
9.7. Porter’s Five Forces Analysis
9.8. Technology Landscape
10.1. Introduction
10.2. Key Market Trends
10.3. Historical and Current Market (2018-2022) and Future Market Analysis (2023-2033) By Type of Therapy [Value (US$ Mn) and Volume Analysis]
10.3.1. Viral Gene Therapy
10.3.2. Non-viral Gene Therapy
10.4. Market Attractiveness Analysis by Type of Therapy
11.1. Introduction
11.2. Historical and Current Market (2018-2022) and Future Market Analysis (2023-2033) By Application [Value (US$ Mn) and Volume Analysis]
11.2.1. Lung Cancer
11.2.2. Breast Cancer
11.2.3. Prostate Cancer
11.2.4. Leukemia
11.2.5. Brain Tumor
11.2.6. Others
11.3. Market Attractiveness Analysis by Application
12.1. Introduction
12.2. Historical and Current Market (2018-2022) and Future Market Analysis (2023-2033) By End User [Value (US$ Mn) and Volume Analysis]
12.2.1. Hospitals
12.2.2. Cancer Research Centers
12.2.3. Biotechnology Companies
12.2.4. Academic Institutions
12.2.5. Others
12.3. Market Attractiveness Analysis by End User
13.1. Introduction
13.2. Key Market Trends
13.3. Historical and Current Market (2018-2022) and Future Market Analysis (2023-2033) By Region [Value (US$ Mn) and Volume Analysis]
13.3.1. North America
13.3.2. Latin America
13.3.3. Europe
13.3.4. Asia-Pacific
13.3.5. Middle East
13.3.6. Africa
13.4. Market Attractiveness Analysis by Region
14.1. Introduction
14.2. Key Market Trends
14.3. Historical and Current Market Size (2018-2022) and Future Market Size Analysis (2023-2033) [Value (US$ Mn) and Volume Analysis]
14.3.1. By Country
14.3.1.1. U.S.
14.3.1.2. Canada
14.3.2. By Type of Therapy
14.3.3. By Application
14.3.4. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Type of Therapy
14.4.3. By Application
14.4.4. By End User
15.1. Introduction
15.2. Key Market Trends
15.3. Historical and Current Market Size (2018-2022) and Future Market Size Analysis (2023-2033) [Value (US$ Mn) and Volume Analysis]
15.3.1. By Country
15.3.1.1. Brazil
15.3.1.2. Mexico
15.3.1.3. Rest of Latin America
15.3.2. By Type of Therapy
15.3.3. By Application
15.3.4. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Type of Therapy
15.4.3. By Application
15.4.4. By End User
16.1. Introduction
16.2. Key Market Trends
16.3. Historical and Current Market Size (2018-2022) and Future Market Size Analysis (2023-2033) [Value (US$ Mn) and Volume Analysis]
16.3.1. By Country
16.3.1.1. Germany
16.3.1.2. Italy
16.3.1.3. France
16.3.1.4. UK
16.3.1.5. Spain
16.3.1.6. Netherlands
16.3.1.7. Norway
16.3.1.8. Russia
16.3.1.9. Rest of Europe
16.3.2. By Type of Therapy
16.3.3. By Application
16.3.4. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Type of Therapy
16.4.3. By Application
16.4.4. By End User
17.1. Introduction
17.2. Key Market Trends
17.3. Historical and Current Market Size (2018-2022) and Future Market Size Analysis (2023-2033) [Value (US$ Mn) and Volume Analysis]
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.1.4. India
17.3.1.5. Indonesia
17.3.1.6. Thailand
17.3.1.7. Vietnam
17.3.1.8. Australia & New Zealand
17.3.1.9. Rest of Asia-Pacific
17.3.2. By Type of Therapy
17.3.3. By Application
17.3.4. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Type of Therapy
17.4.3. By Application
17.4.4. By End User
18.1. Introduction
18.2. Key Market Trends
18.3. Pricing Analysis
18.4. Historical and Current Market Size (2018-2022) and Future Market Size Analysis (2023-2033) [Value (US$ Mn) and Volume Analysis]
18.4.1. By Country
18.4.1.1. Saudi Arabia
18.4.1.2. Turkey
18.4.1.3. U.A.E.
18.4.1.4. Rest of the Middle East
18.4.2. By Type of Therapy
18.4.3. By Application
18.4.4. By End User
18.5. Market Attractiveness Analysis
18.5.1. By Country
18.5.2. By Type of Therapy
18.5.3. By Application
18.5.4. By End User
19.1. Introduction
19.2. Key Market Trends
19.3. Pricing Analysis
19.4. Historical and Current Market Size (2018-2022) and Future Market Size Analysis (2023-2033) [Value (US$ Mn) and Volume Analysis]
19.4.1. By Country
19.4.1.1. South Africa
19.4.1.2. Nigeria
19.4.1.3. Egypt
19.4.1.4. Rest of Africa
19.4.2. By Type of Therapy
19.4.3. By Application
19.4.4. By End User
19.5. Market Attractiveness Analysis
19.5.1. By Country
19.5.2. By Type of Therapy
19.5.3. By Application
19.5.4. By End User
20.1. Tier Structure Breakdown
20.2. Market Share Analysis
20.3. Production Capacity Analysis
20.4. Company Footprint Analysis
20.4.1. Product Footprint of Players
20.4.2. Regional Footprint of Players
20.4.3. Channel Footprint of Players
20.5. Brand Preference Analysis
20.6. Competition Dashboard
21.1. Novartis AG.
21.1.1. Company Overview
21.1.2. Product & Financial Portfolio
21.1.3. Manufacturing Facilities
21.1.4. Recent Developments
21.1.5. SWOT Analysis
21.1.6. Strategy Overview
21.2. Kite Pharma, Inc. (Gilead Sciences, Inc.)
21.3. Bluebird Bio
21.4. Juno Therapeutics (Bristol Myers Squibb)
21.5. Sangamo Therapeutics
21.6. Adaptimmune Therapeutics plc
21.7. Intellia Therapeutics, Inc.
21.8. CRISPR Therapeutics
21.9. Pfizer Inc.
21.10. Merck KGaA
21.11. Amgen Inc.
21.12. CELGENE CORPORATION (Bristol Myers Squibb)
21.13. Spark Therapeutics (Roche)
21.14. Mustang Bio, Inc.
21.15. Gradalis, Inc.
21.16. Tocagen Inc.
21.17. REGENXBIO Inc.
21.18. Cell Genesys, Inc.
21.19. Genelux Corporation
21.20. Vor BioPharma